Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS)

Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is a multicentre observational study of chronic obstructive pulmonary disease (COPD) designed to guide future development of therapies for COPD by providing robust criteria for subclassifying COPD participants into groups most likely to benefit from a given therapy during a clinical trial, and identifying biomarkers/phenotypes that can be used as intermediate outcomes to reliably predict clinical benefit during therapeutic trials. The goal is to enrol 3200 participants in four strata. Participants undergo a baseline visit and three annual follow-up examinations, with quarterly telephone calls. Adjudication of exacerbations and mortality will be undertaken.

[1]  N. Leidy,et al.  Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[2]  N. Anthonisen,et al.  Prognosis in chronic obstructive pulmonary disease. , 1990, The American review of respiratory disease.

[3]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[4]  B. Rubin,et al.  Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis. , 1996, Chest.

[5]  H. Reynolds,et al.  Bronchoalveolar Lavage and Other Methods to Define the Human Respiratory Tract Milieu in Health and Disease , 2011, Lung.

[6]  Jiaquan Xu,et al.  Deaths: preliminary data for 2008. , 2010, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[7]  John Connett,et al.  The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality , 2005, Annals of Internal Medicine.

[8]  Daniel J Buysse,et al.  The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research , 1989, Psychiatry Research.

[9]  J. Wedzicha,et al.  Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.

[10]  J. Hankinson,et al.  Interpretative strategies for lung function tests , 2005, European Respiratory Journal.

[11]  D. Sin,et al.  Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis , 2012, International journal of chronic obstructive pulmonary disease.

[12]  W. MacNee,et al.  Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) , 2008, European Respiratory Journal.

[13]  J. Hankinson,et al.  General considerations for lung function testing , 2005, European Respiratory Journal.

[14]  B. Nicholas,et al.  Induced sputum: a window to lung pathology. , 2009, Biochemical Society transactions.

[15]  J Vestbo,et al.  Developing COPD: a 25 year follow up study of the general population , 2006, Thorax.

[16]  M. Pistolesi,et al.  Outcomes for COPD pharmacological trials: from lung function to biomarkers , 2008, European Respiratory Journal.

[17]  Edwin K Silverman,et al.  Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.

[18]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[19]  J. Martin,et al.  Births: final data for 2008. , 2010, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[20]  K. Strohl,et al.  Using the Berlin Questionnaire To Identify Patients at Risk for the Sleep Apnea Syndrome , 1999, Annals of Internal Medicine.

[21]  Joyce D. Schroeder,et al.  A Combined Pulmonary-Radiology Workshop for Visual Evaluation of COPD: Study Design, Chest CT Findings and Concordance with Quantitative Evaluation , 2012, COPD.

[22]  P. Jones,et al.  Development and first validation of the COPD Assessment Test , 2009, European Respiratory Journal.

[23]  L. Edwards,et al.  Changes in forced expiratory volume in 1 second over time in COPD. , 2011, The New England journal of medicine.

[24]  D. Cella,et al.  Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.

[25]  Sean D Sullivan,et al.  A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  S. Spencer,et al.  Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire. , 2007, Chest.

[27]  P. Barnes.  Emerging pharmacotherapies for COPD. , 2008, Chest.

[28]  J. Hankinson,et al.  Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. , 2010, Chest.

[29]  J. Curtis,et al.  Analysis of the Lung Microbiome in the “Healthy” Smoker and in COPD , 2011, PloS one.

[30]  D. Mannino,et al.  Global burden of COPD: risk factors, prevalence, and future trends , 2007, The Lancet.

[31]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[32]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[33]  R. Snaith,et al.  The Hospital Anxiety and Depression Scale , 1983 .

[34]  Mario Castro,et al.  Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. , 2012, American journal of respiratory and critical care medicine.

[35]  C. Brightling.  Clinical applications of induced sputum. , 2006, Chest.

[36]  V. Froelicher,et al.  Validation of a specific activity questionnaire to estimate exercise tolerance in patients referred for exercise testing. , 2001, American heart journal.

[37]  E. Regan,et al.  Genetic Epidemiology of COPD (COPDGene) Study Design , 2011, COPD.

[38]  J. Vestbo,et al.  COPD: the dangerous underestimate of 15% , 2006, The Lancet.

[39]  C K Wells,et al.  Evaluation of clinical methods for rating dyspnea. , 1988, Chest.

[40]  J. Ware,et al.  A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. , 1996, Medical care.

[41]  J. Vestbo,et al.  Chronic obstructive pulmonary disease biomarker(s) for disease activity needed--urgently. , 2010, American Journal of Respiratory and Critical Care Medicine.

[42]  J. Vestbo,et al.  The many "small COPDs": COPD should be an orphan disease. , 2008, Chest.

[43]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[44]  S. Rennard,et al.  Pathogenesis of COPD , 2005, Seminars in respiratory and critical care medicine.